NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis

Mirum Pharmaceuticals, Inc. (MIRM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MIRM

$100.90

+$0.27 (+0.27%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MIRM with… →

MIRM Key Statistics

As of Sep 4, 2026
Trading
Open
$99.08
Previous Close
$100.63
Day's Range
99.08–101.99
52-Week Range
63.23–130.00
Volume
351.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.49
Valuation
Market Cap
$6.15B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.96
EPS (ttm)Profit attributable to each share over the last twelve months.
−14.08
Financials (FY)
Revenue (FY)
$521.31M+54.74%
Net Income (FY)
−$23.36M
Profit marginThe share of revenue left as profit after all costs and taxes.
−139.18%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
60.98M
1-Year Return
+36.02%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
779.41K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MIRM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+27.74%
2025+91.03%
2024+40.07%
2023+51.38%
2022+22.26%
2021−8.65%
2020−28.79%
2019 (partial year)+85.62%

As of September 4, 2026.

MIRM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$521.31M−$23.36M−4.5%
2024$336.89M−$87.94M−26.1%
2023$186.37M−$163.42M−87.7%
2022$77.06M−$135.67M−176.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$521.31M$421.07M−$22.14M−$23.36M−4.5%
2024$336.89M$255.25M−$87.61M−$87.94M−26.1%
2023$186.37M$139.34M−$109.15M−$163.42M−87.7%
2022$77.06M$64.69M−$131.22M−$135.67M−176.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MIRM Valuation vs Biotechnology Median

Median of 656 stocks
MetricMIRMBiotechnology medianvs median
P/S ratio9.9615.2635% below
Profit margin−139.18%0.00%139.2 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Mirum Pharmaceuticals, Inc. (MIRM) carries a market capitalisation of $6.15B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 433 employees.

Over the past 52 weeks the price has ranged from $63.23 to $130.00. The most recent close on file for MIRM is $100.90, dated September 4, 2026. That is +$0.27 (+0.27%) against the previous close. The latest close sits 59.57% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $521.31M. That is +54.74% against the prior fiscal year, when revenue was $336.89M. The same year closed with a net loss of $23.36M. Profit margin runs at −139.18%. That is 139.2 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −14.08.

Across the 4 fiscal years on file, revenue moves from $77.06M in 2022 to $521.31M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 9.96 times revenue. On price-to-sales that is 34.78% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.49. Daily returns over the trailing 7 years annualize to a volatility of 73.34%. Over the trailing twelve months the price has returned +36.02%. Across 5 years the annualized return works out at +41.16%.

Growth & Income

No dividend is on file for MIRM.

Across the complete calendar years on file, 2025 returned +91.03% and 2020 returned −28.79%. Of the 6 complete calendar years on file, 4 finished higher. So far in 2026 the price is +27.74%.

Peer Comparison

Mirum Pharmaceuticals, Inc. (MIRM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Mirum Pharmaceuticals, Inc. MIRM $6.15B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Mirum Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Visit website →